目的 探讨香连化滞丸联合美沙拉嗪治疗溃疡性结肠炎的临床疗效。方法 纳入驻马店市中医院于2020年1月—2021年6月收治的98例溃疡性结肠炎患者为研究对象，随机分为对照组和治疗组，每组各49例。对照组患者口服美沙拉嗪肠溶片，1 g/次，4次/d，治疗组在对照组的基础口服香连化滞丸，12 g/次，2次/d。两组均治疗12周。观察两组患者临床疗效，比较治疗前后两组患者临床症状缓解时间，二胺氧化酶、D-乳酸、超氧化物歧化酶、丙二醛、转化生长因子-β（TGF-β）、白细胞介素-10（IL-10）和IL-17水平。结果 治疗后，对照组和治疗组总有效率分别为81.63%、95.92%，两组比较差异具有统计学意义（P<0.05）。治疗后，与对照组相比，治疗组血便消失平均时间及腹泻次数至少降低50%所需时间显著缩短（P<0.05）。治疗后，两组二胺氧化酶、D-乳酸、丙二醛和IL-17水平均显著降低，超氧化物歧化酶、TGF-β和IL-10水平显著升高（P<0.05），且治疗组这些指标显著好于对照组（P<0.05）。结论 香连化滞丸联合美沙拉嗪治疗溃疡性结肠炎临床疗效显著，能显著改善溃疡性结肠炎患者的肠道黏膜屏障功能、氧化应激水平及Th17/Treg细胞失衡。

Objective To investigate the clinical efficacy of Xianglian Huazhi Pills combined with mesalazine in treatment of ulcerative colitis. Methods 98 Patients with ulcerative colitis admitted to Zhumadian TCM Hospital from January 2020 to June 2021 were included and randomly divided into control and treatment group, and each group had 49 cases. Patients in the control group were po administered with Mesalazin Enteric-coated Tablets, 1 g/time, four times daily. Patients in the treatment group were po administered with Xianglian Huazhi Pills on the basis of the control group, 12 g/time, twicece daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, the remission time of clinical symptoms, the levels of diamine oxidase, D-lactic acid, superoxide dismutase, malondialdehyde, TGF-β, IL-10, and IL-17 in two groups before and after treatment were compared. Results After treatment, the clinical effective rates of the control group and the treatment group were 81.63% and 95.92% respectively, and there was significant difference between the two groups (P < 0.05). After treatment, compared with the control group, the average time of disappearance of bloody stool and the number of diarrhea were significantly shortened by at least 50% (P < 0.05) in the treatment group. After treatment, the levels of diamine oxidase, D-lactic acid, malondialdehyde, and IL-17 were significantly decreased, while the levels of superoxide dismutase, TGF-β, and IL-10 were significantly increased in two groups(P < 0.05), and these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The clinical effect of Xianglian Huazhi Pills combined with mesalazine in treatment of ulcerative colitis is remarkable, can significantly improve intestinal mucosal barrier function, oxidative stress level and Th17/Treg cell imbalance in patients with ulcerative colitis.

R975